Thrombotic events in patients receiving immune checkpoint inhibitors: Incidence, risk factors, and prognostic outcomes from a retrospective cohort study.
Ali Awada, Ali Ghais, Sary Faraj, Ali Tarhini et autres
e24155 Background: Immune checkpoint inhibitors (ICIs) have transformed cancer outcomes across multiple malignancies. However, emerging evidence suggests that thrombotic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE) are serious complications that may affect survival. The true incidence, timing, risk factors, and …
lb, us (code pays fourni par la source)